T

The Skin Hospital | Darlinghurst Clinic & Day Surgery - Research & Clinical Trials Unit

Research site

(Unclaimed)

Location

121 Crown Street, Darlinghurst, New South Wales, Australia

Site insights

Top conditions

Top treatments

Upadacitinib

Rocatinlimab

PF-06700841

PF-06651600

Ritlecitinib

Dupilumab

LY3009104

Baricitinib

Deucravacitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling

Hair Diseases

Alopecia

Drug: Placebo

Drug: Baricitinib

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to \<18 y...

Enrolling

Plaque Psoriasis

Other: Placebo matching deucravacitinib

Drug: Deucravacitinib